James Matera, DO, on the Renoprotective Effects of SGLT2 Inhibitors in DKD

Dr Matera reviews recent evidence that has demonstrated the potential renal protection offered by sodium glucose co-transporter 2 inhibitors against diabetic kidney disease.

James Matera, DO, FACOI, is a practicing nephrologist, Senior Vice President for Medical Affairs, and Chief Medical Officer at CentraState Medical Center in Freehold, New Jersey.

References:

1. HHS launches President Trump’s “advancing American kidney health” initiative [press release]. July 10, 2019. https://www.hhs.gov/about/news/2019/07/10/hhs-launches-president-trump-advancing-american-kidney-health-initiative.html.
2. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Eng J Med. 2019;380:2295-2306. doi:10.1056/NEJMoa1811744.
3. Tuttle KR, Lakshmanan MC, Rayner B, et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol. 2018;6(8):605-617. https://doi.org/10.1016/S2213-8587(18)30104-9.
4. Walther CP, Richardson P, Winkelmayer WC, et al. ACEi/ARB discontinuation and adverse outcomes in CKD. Presented at: American Society of Nephrology 2019 Kidney Week; November 7, 2019 Washington, DC.